Fibonacci acquires, develops, and transacts drugs.
The Asset Foundry is always on — hunting for best-in-class and first-in-class opportunities.
FIBONACCI ROI MODEL
3X ROI vs. Status Quo Drug Programs
The Math Behind the Magic
Drug discovery is booming, but getting therapies to patients requires a rebuild of drug design, selection, and development. Here's the data.
TIMELINE COMPRESSION ANALYSIS
Phase-by-Phase Breakdown: Discovery to IND
EROOM'S LAW
Drugs Approved per $1B R&D Spend (Indexed)
By automating the operational complexity that drives Eroom's Law—regulatory navigation, protocol optimization, and CMC documentation—we can reverse the productivity decline without changing the underlying science.
The Always-On Drug Hunter.
The industry is full of surplus early-stage assets — a dearth of conviction, not a dearth of biology. We are looking for truly unmet needs we can solve uniquely well.
If you have an asset where the primary blocker is execution speed, regulatory complexity, or missing conviction around the clinical path, we want it.
Contact Business DevelopmentFOUNDRY_CRITERIA
Best-in-Class or First-in-Class
Truly unmet need with a clear differentiation thesis and evidence map.
Clinical Stage
IND-ready or Phase 2 stalled. We accelerate development, not discovery.
Data Rich
Solid preclinical packages. Our agents run on data, not hope.
Operational Bottlenecks
Assets where the primary blocker is execution speed or regulatory complexity.